Clinically localized type 1 and 2 papillary renal cell carcinomas have similar survival outcomes following surgery
PURPOSE: We aimed to determine incidence, pathologic findings, prognostic factors and clinical outcomes for patients with clinically localized papillary RCC.
METHODS: Demographic, clinical and pathologic findings were collected on all patients with PRCC undergoing surgery at four academic medical centers. The primary endpoint was cancer-specific survival (CSS). Relapse-free survival (RFS) and overall survival (OS) were secondary endpoints. Kaplan-Meier estimates were obtained, and Cox proportional hazard regression models were used to assess predictors of mortality and relapse.
RESULTS: We identified 626 PRCC, of which 373 (60 %) were type 1 and 253 (40 %) were type 2, with three-quarters of all tumors being pT1. Compared to patients with type 1, those with type 2 were older (mean age: 63 vs 61; p = 0.02), presented more commonly with symptoms (13 vs 7 %; p = 0.02) and had larger mean tumor size (5.2 vs 4.3 cm; p = 0.001). With a median follow-up of 41 months (IQR: 16-68), 92 patients had died of PRCC (15 %), 48 (8 %) experienced relapse, and 101 died from all causes (16 %). The estimated 5-year CSS, RFS and OS were 83, 91 and 82 %, respectively. In multivariable analysis, older age, T stage and nodal status were predictors of CSS and OS. However, PRCC subtype was not a predictor of CSS, RFS or OS.
CONCLUSION: While patients with type 2 PRCC appear to present with more advanced disease than patients with type 1, PRCC subtype does not appear to be an independent predictor of CSS, RFS or OS for treated localized disease.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
World journal of urology - 34(2016), 5 vom: 25. Mai, Seite 687-93 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ledezma, Rodrigo A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Comparative Study |
|---|
| Anmerkungen: |
Date Completed 18.04.2017 Date Revised 10.04.2022 published: Print-Electronic CommentIn: J Urol. 2017 Jan;197(1):50-51. - PMID 27979566 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00345-015-1692-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM253110211 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM253110211 | ||
| 003 | DE-627 | ||
| 005 | 20231224165528.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00345-015-1692-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0843.xml |
| 035 | |a (DE-627)NLM253110211 | ||
| 035 | |a (NLM)26407582 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ledezma, Rodrigo A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinically localized type 1 and 2 papillary renal cell carcinomas have similar survival outcomes following surgery |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.04.2017 | ||
| 500 | |a Date Revised 10.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: J Urol. 2017 Jan;197(1):50-51. - PMID 27979566 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: We aimed to determine incidence, pathologic findings, prognostic factors and clinical outcomes for patients with clinically localized papillary RCC | ||
| 520 | |a METHODS: Demographic, clinical and pathologic findings were collected on all patients with PRCC undergoing surgery at four academic medical centers. The primary endpoint was cancer-specific survival (CSS). Relapse-free survival (RFS) and overall survival (OS) were secondary endpoints. Kaplan-Meier estimates were obtained, and Cox proportional hazard regression models were used to assess predictors of mortality and relapse | ||
| 520 | |a RESULTS: We identified 626 PRCC, of which 373 (60 %) were type 1 and 253 (40 %) were type 2, with three-quarters of all tumors being pT1. Compared to patients with type 1, those with type 2 were older (mean age: 63 vs 61; p = 0.02), presented more commonly with symptoms (13 vs 7 %; p = 0.02) and had larger mean tumor size (5.2 vs 4.3 cm; p = 0.001). With a median follow-up of 41 months (IQR: 16-68), 92 patients had died of PRCC (15 %), 48 (8 %) experienced relapse, and 101 died from all causes (16 %). The estimated 5-year CSS, RFS and OS were 83, 91 and 82 %, respectively. In multivariable analysis, older age, T stage and nodal status were predictors of CSS and OS. However, PRCC subtype was not a predictor of CSS, RFS or OS | ||
| 520 | |a CONCLUSION: While patients with type 2 PRCC appear to present with more advanced disease than patients with type 1, PRCC subtype does not appear to be an independent predictor of CSS, RFS or OS for treated localized disease | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Histological type | |
| 650 | 4 | |a Papillary RCC | |
| 650 | 4 | |a Prognosis | |
| 650 | 4 | |a Survival | |
| 700 | 1 | |a Negron, Edris |e verfasserin |4 aut | |
| 700 | 1 | |a Paner, Gladell P |e verfasserin |4 aut | |
| 700 | 1 | |a Rjepaj, Chris |e verfasserin |4 aut | |
| 700 | 1 | |a Lascano, Danny |e verfasserin |4 aut | |
| 700 | 1 | |a Haseebuddin, Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a Dangle, Pankaj |e verfasserin |4 aut | |
| 700 | 1 | |a Shalhav, Arieh L |e verfasserin |4 aut | |
| 700 | 1 | |a Crist, Henry |e verfasserin |4 aut | |
| 700 | 1 | |a Raman, Jay D |e verfasserin |4 aut | |
| 700 | 1 | |a Joel DeCastro, G |e verfasserin |4 aut | |
| 700 | 1 | |a Harik, Lara |e verfasserin |4 aut | |
| 700 | 1 | |a Paroder, Monika |e verfasserin |4 aut | |
| 700 | 1 | |a Uzzo, Robert G |e verfasserin |4 aut | |
| 700 | 1 | |a Kutikov, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Eggener, Scott E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t World journal of urology |d 1988 |g 34(2016), 5 vom: 25. Mai, Seite 687-93 |w (DE-627)NLM07484959X |x 1433-8726 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2016 |g number:5 |g day:25 |g month:05 |g pages:687-93 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00345-015-1692-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2016 |e 5 |b 25 |c 05 |h 687-93 | ||